| abstract |
Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer. |